Written questions by Fortune.

Communities and Local Government, what his plans are for the future of Business Improvement Districts.

The Government recognises the important role Business Improvement Districts (BIDs) can play in regeneration and place making. We encourage BIDs to work in partnership with their local authority to deliver growth in their local area. We made a commitment to strengthen BIDs and raise standards in the English Devolution White Paper in December 2024 and we are considering options for reform.

Communities and Local Government, what assessment he has made of the potential merits of introducing simple majority voting in the London Assembly.

The London Assembly is a unique institution in the English Devolution landscape, responsible for scrutiny rather than executive decision-making. It has successfully served the people of London for the last 25 years and will continue to act as the body responsible for scrutinising the Mayor of London.The government will engage with both the Mayor of London and the London Assembly on proposals for improving accountability and scrutiny as set out in the English Devolution White Paper. However, the government has no plans to change voting arrangements in the London Assembly.

What steps she is taking to reduce public spending on Southeastern Railway.

The Government is busy delivering on its plan to overhaul the railways through the creation of Great British Railways, uniting train and track with the focus of delivering for passengers and freight. In June this year, Southeastern and Network Rail Kent route united under a single leadership team known as South Eastern Railway – a significant step towards the creation of Great British Railways. This more collaborative approach is resulting in greater efficiency with better, faster decisions for customers and taxpayers, and reducing the subsidy required to operate Southeastern.

What steps he plans to take to increase the number of GPs in South East London.

The Government committed to recruiting over 1,000 recently qualified general practitioners (GPs) in primary care networks (PCNs) through an £82 million boost to the Additional Roles Reimbursement Scheme (ARRS) over 2024/25, as part of an initiative to secure the future pipeline of GPs. This funding has been continued into 2025/26.Data on the number of recently qualified GPs for which PCNs are claiming reimbursement via the ARRS show that since 1 October 2024, over 2,000 GPs were recruited through the scheme. Several changes have been made to increase the flexibility of the ARRS in 2025/26. This includes GPs and practice nurses included in the main ARRS funding pot, an uplift of the maximum reimbursable rate for GPs in the scheme, and no caps on the number of GPs that can be employed through the scheme.Thanks to new flexibilities under the ARRS, South East London general practices have grown the number of GPs across South East London by approximately 40 working time equivalent between July 2024 and July 2025, utilising the funding offered through this scheme to bring South East London in line with the London average of GPs per 10,000 registered population.NHS South East London has work programmes in place to improve recruitment and retention and has commissioned a package of recruitment and retention support from the South East London Workforce Development Hub, a training hub for general practice.We are investing an additional £1,092 million in general practice to reinforce the front door of the National Health Service, bringing total spend on the GP Contract to £13.4 billion in 2025/26. This is the biggest increase in over a decade. The 8.9% boost to the GP contract in 2025/26 is faster than the 5.8% growth to the NHS budget overall.

What steps she has taken to encourage bus and train operators to reduce levels of disability hate crime on their services.

The government believes that everyone should be able to make journeys on public transport services without fearing that they will become a victim of crime. It is especially concerning that people should experience disability hate crime whilst using buses and trains, and operators must do all they can to challenge such unacceptable behaviour in partnership with relevant authorities. We introduced the Bus Services (No.2) Bill which focuses on delivering safe, more reliable bus networks. The Bill sets requirements for mandatory training on how to recognise and respond appropriately to incidents of criminal and anti-social behaviour, on buses for staff, including drivers and those who deal directly with the travelling public or with issues related to the travelling public. This Bill will also extend requirements for relevant bus staff to undertake training relating to disabled passengers.Provisions in the Bus Services (No 2) Bill would also give all local transport authorities the power to make bus byelaws, which can be enforced by local authority officers on vehicles and at bus stations and stops. This, combined with targeted enforcement, should lead to safer networks. Transport Safety Officers or Transport Safety and Enforcement Officers are also already operating in some areas, including those participating in the Department’s Tackling Anti-Social Behaviour on Transport pilots. The British Transport Police (BTP) are responsible for policing the rail network in England, Scotland and Wales. They take any reports of crime seriously, including disability hate crimes. The BTP works closely with the rail industry, including train operators, to target offenders across the network and ensure it remains a safe environment for passengers and rail staff. The BTP encourage crime to be reported via it is 61016 text number or in an emergency to call 999.

Innovation and Technology, how much funding the Government provided for research into alopecia in the 2023-24 financial year; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). The NIHR supports and delivers research in the following many aspects skin and dermatological conditions including linking genetic research and personalised medicine with common skin diseases such as acne, drug reactions, eczema, and psoriasis and skin cancers including melanoma, squamous cell carcinoma and basal cell carcinoma. It also supports research into skin infections such as herpes simplex, fungal infections, impetigo and cellulitis along with children’s skin disorders and rare skin diseases. UKRI delivers a substantial portfolio of researcher-led projects and strategic investments. Dermatology research supported by MRC covers the breadth of skin and skin associated diseases including inflammatory skin disease, atopic dermatitis (eczema) and skin cancer research. This includes basic biological mechanisms of disease to early-stage interventions such as diagnostics and treatment development. In addition to the individual awards stated below, MRC supports other active research grants in the noted areas through strategic awards made to MRC Research Units.- The Translational skin immunology programme at the MRC Translational Immune Discovery Unit at the University of Oxford investigates the role of T-cells in Inflammatory skin diseases such as psoriasis.- The Translational Melanoma Research Group from the MRC Human Genetics Unit at the University of Edinburgh is investigating the mechanisms of melanoma development & drug resistance through their programme Targeting developmental cell states in melanoma Details of UKRI and NIHR funding on specific areas is provided in the table below: NIHRUKRIAcneNIHR allocated £2,148,574.06 for research concerning acne research in 2023-24.UKRI did not commit any specific funding for acne research in 2023-24.AlopeciaNIHR did not allocate any funds for research concerning alopecia research during 2023-24UKRI have committed £215,666 for alopecia research for a 3 year period commencing March 2024.PsoriasisNIHR allocated £858,946.12 for research concerning psoriasis research in 2023-24.UKRI have committed £300, 266 for psoriasis research for a 3 year period commencing February 2024 .PemphigusNIHR did not allocate any funds for research concerning pemphigus research during 2023-24UKRI did not commit any specific funding for pemphigus research in 2023-24.Atopic DermatitisNIHR allocated £2,045,996 for research concerning atopic dermatitis research in 2023-24.UKRI have committed £404,880 for atopic dermatitis research for a 3 year period commencing June 2023.Epidermolysis BullosaNIHR did not allocate any funds for research concerning epidermolysis bullosa research during 2023-24UKRI did not commit any specific funding for epidermolysis bullosa research in 2023-24.Hidradenitis SuppurativaNIHR has not allocated any funds for research concerning hidradenitis suppurativa research during 2023-24UKRI did not commit any specific funding for hidradenitis suppurativa research in 2023-24.SclerodermaNIHR allocated £155,575 for research concerning scleroderma research in 2023-24.UKRI did not commit any specific funding for scleroderma research in 2023-24.RosaceaNIHR did not allocate any funds concerning rosacea research during 2023-24UKRI did not commit any specific funding for rosacea research in 2023-24.VitiligoNIHR did not allocate any funds for research concerning vitiligo research during 2023-24UKRI did not commit any specific funding for vitiligo research in 2023-24.Basal Cell CarcinomaNIHR did not allocate any funds concerning basal cell carcinoma research during 2023-24UKRI did not commit any specific funding for basal cell carcinoma research in 2023-24.Squamous Cell CarcinomaNIHR allocated £1,467,858 for research concerning squamous cell carcinoma research in 2023-24UKRI did not commit any specific funding for squamous cell carcinoma research in 2023-24.MelanomaNIHR allocated £1,167,536 for research concerning melanoma research in 2023-24UKRI have committed £176,114 for melanoma research between March 24 and August 25.Actinic KeratosisNIHR did not allocate any funds concerning actinic keratosis research during 2023-24UKRI did not commit any specific funding for actinic keratosis research in 2023-24.

Innovation and Technology, how much funding the Government provided for research into psoriasis in the 2023-24 financial year; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). The NIHR supports and delivers research in the following many aspects skin and dermatological conditions including linking genetic research and personalised medicine with common skin diseases such as acne, drug reactions, eczema, and psoriasis and skin cancers including melanoma, squamous cell carcinoma and basal cell carcinoma. It also supports research into skin infections such as herpes simplex, fungal infections, impetigo and cellulitis along with children’s skin disorders and rare skin diseases. UKRI delivers a substantial portfolio of researcher-led projects and strategic investments. Dermatology research supported by MRC covers the breadth of skin and skin associated diseases including inflammatory skin disease, atopic dermatitis (eczema) and skin cancer research. This includes basic biological mechanisms of disease to early-stage interventions such as diagnostics and treatment development. In addition to the individual awards stated below, MRC supports other active research grants in the noted areas through strategic awards made to MRC Research Units.- The Translational skin immunology programme at the MRC Translational Immune Discovery Unit at the University of Oxford investigates the role of T-cells in Inflammatory skin diseases such as psoriasis.- The Translational Melanoma Research Group from the MRC Human Genetics Unit at the University of Edinburgh is investigating the mechanisms of melanoma development & drug resistance through their programme Targeting developmental cell states in melanoma Details of UKRI and NIHR funding on specific areas is provided in the table below: NIHRUKRIAcneNIHR allocated £2,148,574.06 for research concerning acne research in 2023-24.UKRI did not commit any specific funding for acne research in 2023-24.AlopeciaNIHR did not allocate any funds for research concerning alopecia research during 2023-24UKRI have committed £215,666 for alopecia research for a 3 year period commencing March 2024.PsoriasisNIHR allocated £858,946.12 for research concerning psoriasis research in 2023-24.UKRI have committed £300, 266 for psoriasis research for a 3 year period commencing February 2024 .PemphigusNIHR did not allocate any funds for research concerning pemphigus research during 2023-24UKRI did not commit any specific funding for pemphigus research in 2023-24.Atopic DermatitisNIHR allocated £2,045,996 for research concerning atopic dermatitis research in 2023-24.UKRI have committed £404,880 for atopic dermatitis research for a 3 year period commencing June 2023.Epidermolysis BullosaNIHR did not allocate any funds for research concerning epidermolysis bullosa research during 2023-24UKRI did not commit any specific funding for epidermolysis bullosa research in 2023-24.Hidradenitis SuppurativaNIHR has not allocated any funds for research concerning hidradenitis suppurativa research during 2023-24UKRI did not commit any specific funding for hidradenitis suppurativa research in 2023-24.SclerodermaNIHR allocated £155,575 for research concerning scleroderma research in 2023-24.UKRI did not commit any specific funding for scleroderma research in 2023-24.RosaceaNIHR did not allocate any funds concerning rosacea research during 2023-24UKRI did not commit any specific funding for rosacea research in 2023-24.VitiligoNIHR did not allocate any funds for research concerning vitiligo research during 2023-24UKRI did not commit any specific funding for vitiligo research in 2023-24.Basal Cell CarcinomaNIHR did not allocate any funds concerning basal cell carcinoma research during 2023-24UKRI did not commit any specific funding for basal cell carcinoma research in 2023-24.Squamous Cell CarcinomaNIHR allocated £1,467,858 for research concerning squamous cell carcinoma research in 2023-24UKRI did not commit any specific funding for squamous cell carcinoma research in 2023-24.MelanomaNIHR allocated £1,167,536 for research concerning melanoma research in 2023-24UKRI have committed £176,114 for melanoma research between March 24 and August 25.Actinic KeratosisNIHR did not allocate any funds concerning actinic keratosis research during 2023-24UKRI did not commit any specific funding for actinic keratosis research in 2023-24.

Innovation and Technology, how much funding the Government provided for research into vitiligo in the 2023-24 financial year; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). The NIHR supports and delivers research in the following many aspects skin and dermatological conditions including linking genetic research and personalised medicine with common skin diseases such as acne, drug reactions, eczema, and psoriasis and skin cancers including melanoma, squamous cell carcinoma and basal cell carcinoma. It also supports research into skin infections such as herpes simplex, fungal infections, impetigo and cellulitis along with children’s skin disorders and rare skin diseases. UKRI delivers a substantial portfolio of researcher-led projects and strategic investments. Dermatology research supported by MRC covers the breadth of skin and skin associated diseases including inflammatory skin disease, atopic dermatitis (eczema) and skin cancer research. This includes basic biological mechanisms of disease to early-stage interventions such as diagnostics and treatment development. In addition to the individual awards stated below, MRC supports other active research grants in the noted areas through strategic awards made to MRC Research Units.- The Translational skin immunology programme at the MRC Translational Immune Discovery Unit at the University of Oxford investigates the role of T-cells in Inflammatory skin diseases such as psoriasis.- The Translational Melanoma Research Group from the MRC Human Genetics Unit at the University of Edinburgh is investigating the mechanisms of melanoma development & drug resistance through their programme Targeting developmental cell states in melanoma Details of UKRI and NIHR funding on specific areas is provided in the table below: NIHRUKRIAcneNIHR allocated £2,148,574.06 for research concerning acne research in 2023-24.UKRI did not commit any specific funding for acne research in 2023-24.AlopeciaNIHR did not allocate any funds for research concerning alopecia research during 2023-24UKRI have committed £215,666 for alopecia research for a 3 year period commencing March 2024.PsoriasisNIHR allocated £858,946.12 for research concerning psoriasis research in 2023-24.UKRI have committed £300, 266 for psoriasis research for a 3 year period commencing February 2024 .PemphigusNIHR did not allocate any funds for research concerning pemphigus research during 2023-24UKRI did not commit any specific funding for pemphigus research in 2023-24.Atopic DermatitisNIHR allocated £2,045,996 for research concerning atopic dermatitis research in 2023-24.UKRI have committed £404,880 for atopic dermatitis research for a 3 year period commencing June 2023.Epidermolysis BullosaNIHR did not allocate any funds for research concerning epidermolysis bullosa research during 2023-24UKRI did not commit any specific funding for epidermolysis bullosa research in 2023-24.Hidradenitis SuppurativaNIHR has not allocated any funds for research concerning hidradenitis suppurativa research during 2023-24UKRI did not commit any specific funding for hidradenitis suppurativa research in 2023-24.SclerodermaNIHR allocated £155,575 for research concerning scleroderma research in 2023-24.UKRI did not commit any specific funding for scleroderma research in 2023-24.RosaceaNIHR did not allocate any funds concerning rosacea research during 2023-24UKRI did not commit any specific funding for rosacea research in 2023-24.VitiligoNIHR did not allocate any funds for research concerning vitiligo research during 2023-24UKRI did not commit any specific funding for vitiligo research in 2023-24.Basal Cell CarcinomaNIHR did not allocate any funds concerning basal cell carcinoma research during 2023-24UKRI did not commit any specific funding for basal cell carcinoma research in 2023-24.Squamous Cell CarcinomaNIHR allocated £1,467,858 for research concerning squamous cell carcinoma research in 2023-24UKRI did not commit any specific funding for squamous cell carcinoma research in 2023-24.MelanomaNIHR allocated £1,167,536 for research concerning melanoma research in 2023-24UKRI have committed £176,114 for melanoma research between March 24 and August 25.Actinic KeratosisNIHR did not allocate any funds concerning actinic keratosis research during 2023-24UKRI did not commit any specific funding for actinic keratosis research in 2023-24.

Innovation and Technology, how much funding the Government provided for research into hidradenitis suppurativa in the 2023-24 financial year; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). The NIHR supports and delivers research in the following many aspects skin and dermatological conditions including linking genetic research and personalised medicine with common skin diseases such as acne, drug reactions, eczema, and psoriasis and skin cancers including melanoma, squamous cell carcinoma and basal cell carcinoma. It also supports research into skin infections such as herpes simplex, fungal infections, impetigo and cellulitis along with children’s skin disorders and rare skin diseases. UKRI delivers a substantial portfolio of researcher-led projects and strategic investments. Dermatology research supported by MRC covers the breadth of skin and skin associated diseases including inflammatory skin disease, atopic dermatitis (eczema) and skin cancer research. This includes basic biological mechanisms of disease to early-stage interventions such as diagnostics and treatment development. In addition to the individual awards stated below, MRC supports other active research grants in the noted areas through strategic awards made to MRC Research Units.- The Translational skin immunology programme at the MRC Translational Immune Discovery Unit at the University of Oxford investigates the role of T-cells in Inflammatory skin diseases such as psoriasis.- The Translational Melanoma Research Group from the MRC Human Genetics Unit at the University of Edinburgh is investigating the mechanisms of melanoma development & drug resistance through their programme Targeting developmental cell states in melanoma Details of UKRI and NIHR funding on specific areas is provided in the table below: NIHRUKRIAcneNIHR allocated £2,148,574.06 for research concerning acne research in 2023-24.UKRI did not commit any specific funding for acne research in 2023-24.AlopeciaNIHR did not allocate any funds for research concerning alopecia research during 2023-24UKRI have committed £215,666 for alopecia research for a 3 year period commencing March 2024.PsoriasisNIHR allocated £858,946.12 for research concerning psoriasis research in 2023-24.UKRI have committed £300, 266 for psoriasis research for a 3 year period commencing February 2024 .PemphigusNIHR did not allocate any funds for research concerning pemphigus research during 2023-24UKRI did not commit any specific funding for pemphigus research in 2023-24.Atopic DermatitisNIHR allocated £2,045,996 for research concerning atopic dermatitis research in 2023-24.UKRI have committed £404,880 for atopic dermatitis research for a 3 year period commencing June 2023.Epidermolysis BullosaNIHR did not allocate any funds for research concerning epidermolysis bullosa research during 2023-24UKRI did not commit any specific funding for epidermolysis bullosa research in 2023-24.Hidradenitis SuppurativaNIHR has not allocated any funds for research concerning hidradenitis suppurativa research during 2023-24UKRI did not commit any specific funding for hidradenitis suppurativa research in 2023-24.SclerodermaNIHR allocated £155,575 for research concerning scleroderma research in 2023-24.UKRI did not commit any specific funding for scleroderma research in 2023-24.RosaceaNIHR did not allocate any funds concerning rosacea research during 2023-24UKRI did not commit any specific funding for rosacea research in 2023-24.VitiligoNIHR did not allocate any funds for research concerning vitiligo research during 2023-24UKRI did not commit any specific funding for vitiligo research in 2023-24.Basal Cell CarcinomaNIHR did not allocate any funds concerning basal cell carcinoma research during 2023-24UKRI did not commit any specific funding for basal cell carcinoma research in 2023-24.Squamous Cell CarcinomaNIHR allocated £1,467,858 for research concerning squamous cell carcinoma research in 2023-24UKRI did not commit any specific funding for squamous cell carcinoma research in 2023-24.MelanomaNIHR allocated £1,167,536 for research concerning melanoma research in 2023-24UKRI have committed £176,114 for melanoma research between March 24 and August 25.Actinic KeratosisNIHR did not allocate any funds concerning actinic keratosis research during 2023-24UKRI did not commit any specific funding for actinic keratosis research in 2023-24.

Innovation and Technology, how much funding the Government provided for research into actinic keratosis in the 2023-24 financial year; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). The NIHR supports and delivers research in the following many aspects skin and dermatological conditions including linking genetic research and personalised medicine with common skin diseases such as acne, drug reactions, eczema, and psoriasis and skin cancers including melanoma, squamous cell carcinoma and basal cell carcinoma. It also supports research into skin infections such as herpes simplex, fungal infections, impetigo and cellulitis along with children’s skin disorders and rare skin diseases. UKRI delivers a substantial portfolio of researcher-led projects and strategic investments. Dermatology research supported by MRC covers the breadth of skin and skin associated diseases including inflammatory skin disease, atopic dermatitis (eczema) and skin cancer research. This includes basic biological mechanisms of disease to early-stage interventions such as diagnostics and treatment development. In addition to the individual awards stated below, MRC supports other active research grants in the noted areas through strategic awards made to MRC Research Units.- The Translational skin immunology programme at the MRC Translational Immune Discovery Unit at the University of Oxford investigates the role of T-cells in Inflammatory skin diseases such as psoriasis.- The Translational Melanoma Research Group from the MRC Human Genetics Unit at the University of Edinburgh is investigating the mechanisms of melanoma development & drug resistance through their programme Targeting developmental cell states in melanoma Details of UKRI and NIHR funding on specific areas is provided in the table below: NIHRUKRIAcneNIHR allocated £2,148,574.06 for research concerning acne research in 2023-24.UKRI did not commit any specific funding for acne research in 2023-24.AlopeciaNIHR did not allocate any funds for research concerning alopecia research during 2023-24UKRI have committed £215,666 for alopecia research for a 3 year period commencing March 2024.PsoriasisNIHR allocated £858,946.12 for research concerning psoriasis research in 2023-24.UKRI have committed £300, 266 for psoriasis research for a 3 year period commencing February 2024 .PemphigusNIHR did not allocate any funds for research concerning pemphigus research during 2023-24UKRI did not commit any specific funding for pemphigus research in 2023-24.Atopic DermatitisNIHR allocated £2,045,996 for research concerning atopic dermatitis research in 2023-24.UKRI have committed £404,880 for atopic dermatitis research for a 3 year period commencing June 2023.Epidermolysis BullosaNIHR did not allocate any funds for research concerning epidermolysis bullosa research during 2023-24UKRI did not commit any specific funding for epidermolysis bullosa research in 2023-24.Hidradenitis SuppurativaNIHR has not allocated any funds for research concerning hidradenitis suppurativa research during 2023-24UKRI did not commit any specific funding for hidradenitis suppurativa research in 2023-24.SclerodermaNIHR allocated £155,575 for research concerning scleroderma research in 2023-24.UKRI did not commit any specific funding for scleroderma research in 2023-24.RosaceaNIHR did not allocate any funds concerning rosacea research during 2023-24UKRI did not commit any specific funding for rosacea research in 2023-24.VitiligoNIHR did not allocate any funds for research concerning vitiligo research during 2023-24UKRI did not commit any specific funding for vitiligo research in 2023-24.Basal Cell CarcinomaNIHR did not allocate any funds concerning basal cell carcinoma research during 2023-24UKRI did not commit any specific funding for basal cell carcinoma research in 2023-24.Squamous Cell CarcinomaNIHR allocated £1,467,858 for research concerning squamous cell carcinoma research in 2023-24UKRI did not commit any specific funding for squamous cell carcinoma research in 2023-24.MelanomaNIHR allocated £1,167,536 for research concerning melanoma research in 2023-24UKRI have committed £176,114 for melanoma research between March 24 and August 25.Actinic KeratosisNIHR did not allocate any funds concerning actinic keratosis research during 2023-24UKRI did not commit any specific funding for actinic keratosis research in 2023-24.

Innovation and Technology, how much funding the Government provided for research into scleroderma in the 2023-24 financial year; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). The NIHR supports and delivers research in the following many aspects skin and dermatological conditions including linking genetic research and personalised medicine with common skin diseases such as acne, drug reactions, eczema, and psoriasis and skin cancers including melanoma, squamous cell carcinoma and basal cell carcinoma. It also supports research into skin infections such as herpes simplex, fungal infections, impetigo and cellulitis along with children’s skin disorders and rare skin diseases. UKRI delivers a substantial portfolio of researcher-led projects and strategic investments. Dermatology research supported by MRC covers the breadth of skin and skin associated diseases including inflammatory skin disease, atopic dermatitis (eczema) and skin cancer research. This includes basic biological mechanisms of disease to early-stage interventions such as diagnostics and treatment development. In addition to the individual awards stated below, MRC supports other active research grants in the noted areas through strategic awards made to MRC Research Units.- The Translational skin immunology programme at the MRC Translational Immune Discovery Unit at the University of Oxford investigates the role of T-cells in Inflammatory skin diseases such as psoriasis.- The Translational Melanoma Research Group from the MRC Human Genetics Unit at the University of Edinburgh is investigating the mechanisms of melanoma development & drug resistance through their programme Targeting developmental cell states in melanoma Details of UKRI and NIHR funding on specific areas is provided in the table below: NIHRUKRIAcneNIHR allocated £2,148,574.06 for research concerning acne research in 2023-24.UKRI did not commit any specific funding for acne research in 2023-24.AlopeciaNIHR did not allocate any funds for research concerning alopecia research during 2023-24UKRI have committed £215,666 for alopecia research for a 3 year period commencing March 2024.PsoriasisNIHR allocated £858,946.12 for research concerning psoriasis research in 2023-24.UKRI have committed £300, 266 for psoriasis research for a 3 year period commencing February 2024 .PemphigusNIHR did not allocate any funds for research concerning pemphigus research during 2023-24UKRI did not commit any specific funding for pemphigus research in 2023-24.Atopic DermatitisNIHR allocated £2,045,996 for research concerning atopic dermatitis research in 2023-24.UKRI have committed £404,880 for atopic dermatitis research for a 3 year period commencing June 2023.Epidermolysis BullosaNIHR did not allocate any funds for research concerning epidermolysis bullosa research during 2023-24UKRI did not commit any specific funding for epidermolysis bullosa research in 2023-24.Hidradenitis SuppurativaNIHR has not allocated any funds for research concerning hidradenitis suppurativa research during 2023-24UKRI did not commit any specific funding for hidradenitis suppurativa research in 2023-24.SclerodermaNIHR allocated £155,575 for research concerning scleroderma research in 2023-24.UKRI did not commit any specific funding for scleroderma research in 2023-24.RosaceaNIHR did not allocate any funds concerning rosacea research during 2023-24UKRI did not commit any specific funding for rosacea research in 2023-24.VitiligoNIHR did not allocate any funds for research concerning vitiligo research during 2023-24UKRI did not commit any specific funding for vitiligo research in 2023-24.Basal Cell CarcinomaNIHR did not allocate any funds concerning basal cell carcinoma research during 2023-24UKRI did not commit any specific funding for basal cell carcinoma research in 2023-24.Squamous Cell CarcinomaNIHR allocated £1,467,858 for research concerning squamous cell carcinoma research in 2023-24UKRI did not commit any specific funding for squamous cell carcinoma research in 2023-24.MelanomaNIHR allocated £1,167,536 for research concerning melanoma research in 2023-24UKRI have committed £176,114 for melanoma research between March 24 and August 25.Actinic KeratosisNIHR did not allocate any funds concerning actinic keratosis research during 2023-24UKRI did not commit any specific funding for actinic keratosis research in 2023-24.

Innovation and Technology, how much funding the Government provided for research into epidermolysis bullosa in the 2023-24 financial year; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). The NIHR supports and delivers research in the following many aspects skin and dermatological conditions including linking genetic research and personalised medicine with common skin diseases such as acne, drug reactions, eczema, and psoriasis and skin cancers including melanoma, squamous cell carcinoma and basal cell carcinoma. It also supports research into skin infections such as herpes simplex, fungal infections, impetigo and cellulitis along with children’s skin disorders and rare skin diseases. UKRI delivers a substantial portfolio of researcher-led projects and strategic investments. Dermatology research supported by MRC covers the breadth of skin and skin associated diseases including inflammatory skin disease, atopic dermatitis (eczema) and skin cancer research. This includes basic biological mechanisms of disease to early-stage interventions such as diagnostics and treatment development. In addition to the individual awards stated below, MRC supports other active research grants in the noted areas through strategic awards made to MRC Research Units.- The Translational skin immunology programme at the MRC Translational Immune Discovery Unit at the University of Oxford investigates the role of T-cells in Inflammatory skin diseases such as psoriasis.- The Translational Melanoma Research Group from the MRC Human Genetics Unit at the University of Edinburgh is investigating the mechanisms of melanoma development & drug resistance through their programme Targeting developmental cell states in melanoma Details of UKRI and NIHR funding on specific areas is provided in the table below: NIHRUKRIAcneNIHR allocated £2,148,574.06 for research concerning acne research in 2023-24.UKRI did not commit any specific funding for acne research in 2023-24.AlopeciaNIHR did not allocate any funds for research concerning alopecia research during 2023-24UKRI have committed £215,666 for alopecia research for a 3 year period commencing March 2024.PsoriasisNIHR allocated £858,946.12 for research concerning psoriasis research in 2023-24.UKRI have committed £300, 266 for psoriasis research for a 3 year period commencing February 2024 .PemphigusNIHR did not allocate any funds for research concerning pemphigus research during 2023-24UKRI did not commit any specific funding for pemphigus research in 2023-24.Atopic DermatitisNIHR allocated £2,045,996 for research concerning atopic dermatitis research in 2023-24.UKRI have committed £404,880 for atopic dermatitis research for a 3 year period commencing June 2023.Epidermolysis BullosaNIHR did not allocate any funds for research concerning epidermolysis bullosa research during 2023-24UKRI did not commit any specific funding for epidermolysis bullosa research in 2023-24.Hidradenitis SuppurativaNIHR has not allocated any funds for research concerning hidradenitis suppurativa research during 2023-24UKRI did not commit any specific funding for hidradenitis suppurativa research in 2023-24.SclerodermaNIHR allocated £155,575 for research concerning scleroderma research in 2023-24.UKRI did not commit any specific funding for scleroderma research in 2023-24.RosaceaNIHR did not allocate any funds concerning rosacea research during 2023-24UKRI did not commit any specific funding for rosacea research in 2023-24.VitiligoNIHR did not allocate any funds for research concerning vitiligo research during 2023-24UKRI did not commit any specific funding for vitiligo research in 2023-24.Basal Cell CarcinomaNIHR did not allocate any funds concerning basal cell carcinoma research during 2023-24UKRI did not commit any specific funding for basal cell carcinoma research in 2023-24.Squamous Cell CarcinomaNIHR allocated £1,467,858 for research concerning squamous cell carcinoma research in 2023-24UKRI did not commit any specific funding for squamous cell carcinoma research in 2023-24.MelanomaNIHR allocated £1,167,536 for research concerning melanoma research in 2023-24UKRI have committed £176,114 for melanoma research between March 24 and August 25.Actinic KeratosisNIHR did not allocate any funds concerning actinic keratosis research during 2023-24UKRI did not commit any specific funding for actinic keratosis research in 2023-24.

Innovation and Technology, how much funding the Government provided for research into squamous cell carcinoma in the 2023-24 financial year; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). The NIHR supports and delivers research in the following many aspects skin and dermatological conditions including linking genetic research and personalised medicine with common skin diseases such as acne, drug reactions, eczema, and psoriasis and skin cancers including melanoma, squamous cell carcinoma and basal cell carcinoma. It also supports research into skin infections such as herpes simplex, fungal infections, impetigo and cellulitis along with children’s skin disorders and rare skin diseases. UKRI delivers a substantial portfolio of researcher-led projects and strategic investments. Dermatology research supported by MRC covers the breadth of skin and skin associated diseases including inflammatory skin disease, atopic dermatitis (eczema) and skin cancer research. This includes basic biological mechanisms of disease to early-stage interventions such as diagnostics and treatment development. In addition to the individual awards stated below, MRC supports other active research grants in the noted areas through strategic awards made to MRC Research Units.- The Translational skin immunology programme at the MRC Translational Immune Discovery Unit at the University of Oxford investigates the role of T-cells in Inflammatory skin diseases such as psoriasis.- The Translational Melanoma Research Group from the MRC Human Genetics Unit at the University of Edinburgh is investigating the mechanisms of melanoma development & drug resistance through their programme Targeting developmental cell states in melanoma Details of UKRI and NIHR funding on specific areas is provided in the table below: NIHRUKRIAcneNIHR allocated £2,148,574.06 for research concerning acne research in 2023-24.UKRI did not commit any specific funding for acne research in 2023-24.AlopeciaNIHR did not allocate any funds for research concerning alopecia research during 2023-24UKRI have committed £215,666 for alopecia research for a 3 year period commencing March 2024.PsoriasisNIHR allocated £858,946.12 for research concerning psoriasis research in 2023-24.UKRI have committed £300, 266 for psoriasis research for a 3 year period commencing February 2024 .PemphigusNIHR did not allocate any funds for research concerning pemphigus research during 2023-24UKRI did not commit any specific funding for pemphigus research in 2023-24.Atopic DermatitisNIHR allocated £2,045,996 for research concerning atopic dermatitis research in 2023-24.UKRI have committed £404,880 for atopic dermatitis research for a 3 year period commencing June 2023.Epidermolysis BullosaNIHR did not allocate any funds for research concerning epidermolysis bullosa research during 2023-24UKRI did not commit any specific funding for epidermolysis bullosa research in 2023-24.Hidradenitis SuppurativaNIHR has not allocated any funds for research concerning hidradenitis suppurativa research during 2023-24UKRI did not commit any specific funding for hidradenitis suppurativa research in 2023-24.SclerodermaNIHR allocated £155,575 for research concerning scleroderma research in 2023-24.UKRI did not commit any specific funding for scleroderma research in 2023-24.RosaceaNIHR did not allocate any funds concerning rosacea research during 2023-24UKRI did not commit any specific funding for rosacea research in 2023-24.VitiligoNIHR did not allocate any funds for research concerning vitiligo research during 2023-24UKRI did not commit any specific funding for vitiligo research in 2023-24.Basal Cell CarcinomaNIHR did not allocate any funds concerning basal cell carcinoma research during 2023-24UKRI did not commit any specific funding for basal cell carcinoma research in 2023-24.Squamous Cell CarcinomaNIHR allocated £1,467,858 for research concerning squamous cell carcinoma research in 2023-24UKRI did not commit any specific funding for squamous cell carcinoma research in 2023-24.MelanomaNIHR allocated £1,167,536 for research concerning melanoma research in 2023-24UKRI have committed £176,114 for melanoma research between March 24 and August 25.Actinic KeratosisNIHR did not allocate any funds concerning actinic keratosis research during 2023-24UKRI did not commit any specific funding for actinic keratosis research in 2023-24.

Innovation and Technology, how much funding the Government provided for research into basal cell carcinoma in the 2023-24 financial year; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). The NIHR supports and delivers research in the following many aspects skin and dermatological conditions including linking genetic research and personalised medicine with common skin diseases such as acne, drug reactions, eczema, and psoriasis and skin cancers including melanoma, squamous cell carcinoma and basal cell carcinoma. It also supports research into skin infections such as herpes simplex, fungal infections, impetigo and cellulitis along with children’s skin disorders and rare skin diseases. UKRI delivers a substantial portfolio of researcher-led projects and strategic investments. Dermatology research supported by MRC covers the breadth of skin and skin associated diseases including inflammatory skin disease, atopic dermatitis (eczema) and skin cancer research. This includes basic biological mechanisms of disease to early-stage interventions such as diagnostics and treatment development. In addition to the individual awards stated below, MRC supports other active research grants in the noted areas through strategic awards made to MRC Research Units.- The Translational skin immunology programme at the MRC Translational Immune Discovery Unit at the University of Oxford investigates the role of T-cells in Inflammatory skin diseases such as psoriasis.- The Translational Melanoma Research Group from the MRC Human Genetics Unit at the University of Edinburgh is investigating the mechanisms of melanoma development & drug resistance through their programme Targeting developmental cell states in melanoma Details of UKRI and NIHR funding on specific areas is provided in the table below: NIHRUKRIAcneNIHR allocated £2,148,574.06 for research concerning acne research in 2023-24.UKRI did not commit any specific funding for acne research in 2023-24.AlopeciaNIHR did not allocate any funds for research concerning alopecia research during 2023-24UKRI have committed £215,666 for alopecia research for a 3 year period commencing March 2024.PsoriasisNIHR allocated £858,946.12 for research concerning psoriasis research in 2023-24.UKRI have committed £300, 266 for psoriasis research for a 3 year period commencing February 2024 .PemphigusNIHR did not allocate any funds for research concerning pemphigus research during 2023-24UKRI did not commit any specific funding for pemphigus research in 2023-24.Atopic DermatitisNIHR allocated £2,045,996 for research concerning atopic dermatitis research in 2023-24.UKRI have committed £404,880 for atopic dermatitis research for a 3 year period commencing June 2023.Epidermolysis BullosaNIHR did not allocate any funds for research concerning epidermolysis bullosa research during 2023-24UKRI did not commit any specific funding for epidermolysis bullosa research in 2023-24.Hidradenitis SuppurativaNIHR has not allocated any funds for research concerning hidradenitis suppurativa research during 2023-24UKRI did not commit any specific funding for hidradenitis suppurativa research in 2023-24.SclerodermaNIHR allocated £155,575 for research concerning scleroderma research in 2023-24.UKRI did not commit any specific funding for scleroderma research in 2023-24.RosaceaNIHR did not allocate any funds concerning rosacea research during 2023-24UKRI did not commit any specific funding for rosacea research in 2023-24.VitiligoNIHR did not allocate any funds for research concerning vitiligo research during 2023-24UKRI did not commit any specific funding for vitiligo research in 2023-24.Basal Cell CarcinomaNIHR did not allocate any funds concerning basal cell carcinoma research during 2023-24UKRI did not commit any specific funding for basal cell carcinoma research in 2023-24.Squamous Cell CarcinomaNIHR allocated £1,467,858 for research concerning squamous cell carcinoma research in 2023-24UKRI did not commit any specific funding for squamous cell carcinoma research in 2023-24.MelanomaNIHR allocated £1,167,536 for research concerning melanoma research in 2023-24UKRI have committed £176,114 for melanoma research between March 24 and August 25.Actinic KeratosisNIHR did not allocate any funds concerning actinic keratosis research during 2023-24UKRI did not commit any specific funding for actinic keratosis research in 2023-24.

Innovation and Technology, how much funding the Government provided for research into rosacea in the 2023-24 financial year; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). The NIHR supports and delivers research in the following many aspects skin and dermatological conditions including linking genetic research and personalised medicine with common skin diseases such as acne, drug reactions, eczema, and psoriasis and skin cancers including melanoma, squamous cell carcinoma and basal cell carcinoma. It also supports research into skin infections such as herpes simplex, fungal infections, impetigo and cellulitis along with children’s skin disorders and rare skin diseases. UKRI delivers a substantial portfolio of researcher-led projects and strategic investments. Dermatology research supported by MRC covers the breadth of skin and skin associated diseases including inflammatory skin disease, atopic dermatitis (eczema) and skin cancer research. This includes basic biological mechanisms of disease to early-stage interventions such as diagnostics and treatment development. In addition to the individual awards stated below, MRC supports other active research grants in the noted areas through strategic awards made to MRC Research Units.- The Translational skin immunology programme at the MRC Translational Immune Discovery Unit at the University of Oxford investigates the role of T-cells in Inflammatory skin diseases such as psoriasis.- The Translational Melanoma Research Group from the MRC Human Genetics Unit at the University of Edinburgh is investigating the mechanisms of melanoma development & drug resistance through their programme Targeting developmental cell states in melanoma Details of UKRI and NIHR funding on specific areas is provided in the table below: NIHRUKRIAcneNIHR allocated £2,148,574.06 for research concerning acne research in 2023-24.UKRI did not commit any specific funding for acne research in 2023-24.AlopeciaNIHR did not allocate any funds for research concerning alopecia research during 2023-24UKRI have committed £215,666 for alopecia research for a 3 year period commencing March 2024.PsoriasisNIHR allocated £858,946.12 for research concerning psoriasis research in 2023-24.UKRI have committed £300, 266 for psoriasis research for a 3 year period commencing February 2024 .PemphigusNIHR did not allocate any funds for research concerning pemphigus research during 2023-24UKRI did not commit any specific funding for pemphigus research in 2023-24.Atopic DermatitisNIHR allocated £2,045,996 for research concerning atopic dermatitis research in 2023-24.UKRI have committed £404,880 for atopic dermatitis research for a 3 year period commencing June 2023.Epidermolysis BullosaNIHR did not allocate any funds for research concerning epidermolysis bullosa research during 2023-24UKRI did not commit any specific funding for epidermolysis bullosa research in 2023-24.Hidradenitis SuppurativaNIHR has not allocated any funds for research concerning hidradenitis suppurativa research during 2023-24UKRI did not commit any specific funding for hidradenitis suppurativa research in 2023-24.SclerodermaNIHR allocated £155,575 for research concerning scleroderma research in 2023-24.UKRI did not commit any specific funding for scleroderma research in 2023-24.RosaceaNIHR did not allocate any funds concerning rosacea research during 2023-24UKRI did not commit any specific funding for rosacea research in 2023-24.VitiligoNIHR did not allocate any funds for research concerning vitiligo research during 2023-24UKRI did not commit any specific funding for vitiligo research in 2023-24.Basal Cell CarcinomaNIHR did not allocate any funds concerning basal cell carcinoma research during 2023-24UKRI did not commit any specific funding for basal cell carcinoma research in 2023-24.Squamous Cell CarcinomaNIHR allocated £1,467,858 for research concerning squamous cell carcinoma research in 2023-24UKRI did not commit any specific funding for squamous cell carcinoma research in 2023-24.MelanomaNIHR allocated £1,167,536 for research concerning melanoma research in 2023-24UKRI have committed £176,114 for melanoma research between March 24 and August 25.Actinic KeratosisNIHR did not allocate any funds concerning actinic keratosis research during 2023-24UKRI did not commit any specific funding for actinic keratosis research in 2023-24.

Innovation and Technology, how much funding the Government provided for research into melanoma in the 2023-24 financial year; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). The NIHR supports and delivers research in the following many aspects skin and dermatological conditions including linking genetic research and personalised medicine with common skin diseases such as acne, drug reactions, eczema, and psoriasis and skin cancers including melanoma, squamous cell carcinoma and basal cell carcinoma. It also supports research into skin infections such as herpes simplex, fungal infections, impetigo and cellulitis along with children’s skin disorders and rare skin diseases. UKRI delivers a substantial portfolio of researcher-led projects and strategic investments. Dermatology research supported by MRC covers the breadth of skin and skin associated diseases including inflammatory skin disease, atopic dermatitis (eczema) and skin cancer research. This includes basic biological mechanisms of disease to early-stage interventions such as diagnostics and treatment development. In addition to the individual awards stated below, MRC supports other active research grants in the noted areas through strategic awards made to MRC Research Units.- The Translational skin immunology programme at the MRC Translational Immune Discovery Unit at the University of Oxford investigates the role of T-cells in Inflammatory skin diseases such as psoriasis.- The Translational Melanoma Research Group from the MRC Human Genetics Unit at the University of Edinburgh is investigating the mechanisms of melanoma development & drug resistance through their programme Targeting developmental cell states in melanoma Details of UKRI and NIHR funding on specific areas is provided in the table below: NIHRUKRIAcneNIHR allocated £2,148,574.06 for research concerning acne research in 2023-24.UKRI did not commit any specific funding for acne research in 2023-24.AlopeciaNIHR did not allocate any funds for research concerning alopecia research during 2023-24UKRI have committed £215,666 for alopecia research for a 3 year period commencing March 2024.PsoriasisNIHR allocated £858,946.12 for research concerning psoriasis research in 2023-24.UKRI have committed £300, 266 for psoriasis research for a 3 year period commencing February 2024 .PemphigusNIHR did not allocate any funds for research concerning pemphigus research during 2023-24UKRI did not commit any specific funding for pemphigus research in 2023-24.Atopic DermatitisNIHR allocated £2,045,996 for research concerning atopic dermatitis research in 2023-24.UKRI have committed £404,880 for atopic dermatitis research for a 3 year period commencing June 2023.Epidermolysis BullosaNIHR did not allocate any funds for research concerning epidermolysis bullosa research during 2023-24UKRI did not commit any specific funding for epidermolysis bullosa research in 2023-24.Hidradenitis SuppurativaNIHR has not allocated any funds for research concerning hidradenitis suppurativa research during 2023-24UKRI did not commit any specific funding for hidradenitis suppurativa research in 2023-24.SclerodermaNIHR allocated £155,575 for research concerning scleroderma research in 2023-24.UKRI did not commit any specific funding for scleroderma research in 2023-24.RosaceaNIHR did not allocate any funds concerning rosacea research during 2023-24UKRI did not commit any specific funding for rosacea research in 2023-24.VitiligoNIHR did not allocate any funds for research concerning vitiligo research during 2023-24UKRI did not commit any specific funding for vitiligo research in 2023-24.Basal Cell CarcinomaNIHR did not allocate any funds concerning basal cell carcinoma research during 2023-24UKRI did not commit any specific funding for basal cell carcinoma research in 2023-24.Squamous Cell CarcinomaNIHR allocated £1,467,858 for research concerning squamous cell carcinoma research in 2023-24UKRI did not commit any specific funding for squamous cell carcinoma research in 2023-24.MelanomaNIHR allocated £1,167,536 for research concerning melanoma research in 2023-24UKRI have committed £176,114 for melanoma research between March 24 and August 25.Actinic KeratosisNIHR did not allocate any funds concerning actinic keratosis research during 2023-24UKRI did not commit any specific funding for actinic keratosis research in 2023-24.

Innovation and Technology, how much funding the Government provided for research into acne in the 2023-24 financial year; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). The NIHR supports and delivers research in the following many aspects skin and dermatological conditions including linking genetic research and personalised medicine with common skin diseases such as acne, drug reactions, eczema, and psoriasis and skin cancers including melanoma, squamous cell carcinoma and basal cell carcinoma. It also supports research into skin infections such as herpes simplex, fungal infections, impetigo and cellulitis along with children’s skin disorders and rare skin diseases. UKRI delivers a substantial portfolio of researcher-led projects and strategic investments. Dermatology research supported by MRC covers the breadth of skin and skin associated diseases including inflammatory skin disease, atopic dermatitis (eczema) and skin cancer research. This includes basic biological mechanisms of disease to early-stage interventions such as diagnostics and treatment development. In addition to the individual awards stated below, MRC supports other active research grants in the noted areas through strategic awards made to MRC Research Units.- The Translational skin immunology programme at the MRC Translational Immune Discovery Unit at the University of Oxford investigates the role of T-cells in Inflammatory skin diseases such as psoriasis.- The Translational Melanoma Research Group from the MRC Human Genetics Unit at the University of Edinburgh is investigating the mechanisms of melanoma development & drug resistance through their programme Targeting developmental cell states in melanoma Details of UKRI and NIHR funding on specific areas is provided in the table below: NIHRUKRIAcneNIHR allocated £2,148,574.06 for research concerning acne research in 2023-24.UKRI did not commit any specific funding for acne research in 2023-24.AlopeciaNIHR did not allocate any funds for research concerning alopecia research during 2023-24UKRI have committed £215,666 for alopecia research for a 3 year period commencing March 2024.PsoriasisNIHR allocated £858,946.12 for research concerning psoriasis research in 2023-24.UKRI have committed £300, 266 for psoriasis research for a 3 year period commencing February 2024 .PemphigusNIHR did not allocate any funds for research concerning pemphigus research during 2023-24UKRI did not commit any specific funding for pemphigus research in 2023-24.Atopic DermatitisNIHR allocated £2,045,996 for research concerning atopic dermatitis research in 2023-24.UKRI have committed £404,880 for atopic dermatitis research for a 3 year period commencing June 2023.Epidermolysis BullosaNIHR did not allocate any funds for research concerning epidermolysis bullosa research during 2023-24UKRI did not commit any specific funding for epidermolysis bullosa research in 2023-24.Hidradenitis SuppurativaNIHR has not allocated any funds for research concerning hidradenitis suppurativa research during 2023-24UKRI did not commit any specific funding for hidradenitis suppurativa research in 2023-24.SclerodermaNIHR allocated £155,575 for research concerning scleroderma research in 2023-24.UKRI did not commit any specific funding for scleroderma research in 2023-24.RosaceaNIHR did not allocate any funds concerning rosacea research during 2023-24UKRI did not commit any specific funding for rosacea research in 2023-24.VitiligoNIHR did not allocate any funds for research concerning vitiligo research during 2023-24UKRI did not commit any specific funding for vitiligo research in 2023-24.Basal Cell CarcinomaNIHR did not allocate any funds concerning basal cell carcinoma research during 2023-24UKRI did not commit any specific funding for basal cell carcinoma research in 2023-24.Squamous Cell CarcinomaNIHR allocated £1,467,858 for research concerning squamous cell carcinoma research in 2023-24UKRI did not commit any specific funding for squamous cell carcinoma research in 2023-24.MelanomaNIHR allocated £1,167,536 for research concerning melanoma research in 2023-24UKRI have committed £176,114 for melanoma research between March 24 and August 25.Actinic KeratosisNIHR did not allocate any funds concerning actinic keratosis research during 2023-24UKRI did not commit any specific funding for actinic keratosis research in 2023-24.

Innovation and Technology, how much funding the Government provided for research into pemphigus in the 2023-24 financial year; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). The NIHR supports and delivers research in the following many aspects skin and dermatological conditions including linking genetic research and personalised medicine with common skin diseases such as acne, drug reactions, eczema, and psoriasis and skin cancers including melanoma, squamous cell carcinoma and basal cell carcinoma. It also supports research into skin infections such as herpes simplex, fungal infections, impetigo and cellulitis along with children’s skin disorders and rare skin diseases. UKRI delivers a substantial portfolio of researcher-led projects and strategic investments. Dermatology research supported by MRC covers the breadth of skin and skin associated diseases including inflammatory skin disease, atopic dermatitis (eczema) and skin cancer research. This includes basic biological mechanisms of disease to early-stage interventions such as diagnostics and treatment development. In addition to the individual awards stated below, MRC supports other active research grants in the noted areas through strategic awards made to MRC Research Units.- The Translational skin immunology programme at the MRC Translational Immune Discovery Unit at the University of Oxford investigates the role of T-cells in Inflammatory skin diseases such as psoriasis.- The Translational Melanoma Research Group from the MRC Human Genetics Unit at the University of Edinburgh is investigating the mechanisms of melanoma development & drug resistance through their programme Targeting developmental cell states in melanoma Details of UKRI and NIHR funding on specific areas is provided in the table below: NIHRUKRIAcneNIHR allocated £2,148,574.06 for research concerning acne research in 2023-24.UKRI did not commit any specific funding for acne research in 2023-24.AlopeciaNIHR did not allocate any funds for research concerning alopecia research during 2023-24UKRI have committed £215,666 for alopecia research for a 3 year period commencing March 2024.PsoriasisNIHR allocated £858,946.12 for research concerning psoriasis research in 2023-24.UKRI have committed £300, 266 for psoriasis research for a 3 year period commencing February 2024 .PemphigusNIHR did not allocate any funds for research concerning pemphigus research during 2023-24UKRI did not commit any specific funding for pemphigus research in 2023-24.Atopic DermatitisNIHR allocated £2,045,996 for research concerning atopic dermatitis research in 2023-24.UKRI have committed £404,880 for atopic dermatitis research for a 3 year period commencing June 2023.Epidermolysis BullosaNIHR did not allocate any funds for research concerning epidermolysis bullosa research during 2023-24UKRI did not commit any specific funding for epidermolysis bullosa research in 2023-24.Hidradenitis SuppurativaNIHR has not allocated any funds for research concerning hidradenitis suppurativa research during 2023-24UKRI did not commit any specific funding for hidradenitis suppurativa research in 2023-24.SclerodermaNIHR allocated £155,575 for research concerning scleroderma research in 2023-24.UKRI did not commit any specific funding for scleroderma research in 2023-24.RosaceaNIHR did not allocate any funds concerning rosacea research during 2023-24UKRI did not commit any specific funding for rosacea research in 2023-24.VitiligoNIHR did not allocate any funds for research concerning vitiligo research during 2023-24UKRI did not commit any specific funding for vitiligo research in 2023-24.Basal Cell CarcinomaNIHR did not allocate any funds concerning basal cell carcinoma research during 2023-24UKRI did not commit any specific funding for basal cell carcinoma research in 2023-24.Squamous Cell CarcinomaNIHR allocated £1,467,858 for research concerning squamous cell carcinoma research in 2023-24UKRI did not commit any specific funding for squamous cell carcinoma research in 2023-24.MelanomaNIHR allocated £1,167,536 for research concerning melanoma research in 2023-24UKRI have committed £176,114 for melanoma research between March 24 and August 25.Actinic KeratosisNIHR did not allocate any funds concerning actinic keratosis research during 2023-24UKRI did not commit any specific funding for actinic keratosis research in 2023-24.

Innovation and Technology, how much funding the Government provided for research into atopic dermatitis in the 2023-24 financial year; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). The NIHR supports and delivers research in the following many aspects skin and dermatological conditions including linking genetic research and personalised medicine with common skin diseases such as acne, drug reactions, eczema, and psoriasis and skin cancers including melanoma, squamous cell carcinoma and basal cell carcinoma. It also supports research into skin infections such as herpes simplex, fungal infections, impetigo and cellulitis along with children’s skin disorders and rare skin diseases. UKRI delivers a substantial portfolio of researcher-led projects and strategic investments. Dermatology research supported by MRC covers the breadth of skin and skin associated diseases including inflammatory skin disease, atopic dermatitis (eczema) and skin cancer research. This includes basic biological mechanisms of disease to early-stage interventions such as diagnostics and treatment development. In addition to the individual awards stated below, MRC supports other active research grants in the noted areas through strategic awards made to MRC Research Units.- The Translational skin immunology programme at the MRC Translational Immune Discovery Unit at the University of Oxford investigates the role of T-cells in Inflammatory skin diseases such as psoriasis.- The Translational Melanoma Research Group from the MRC Human Genetics Unit at the University of Edinburgh is investigating the mechanisms of melanoma development & drug resistance through their programme Targeting developmental cell states in melanoma Details of UKRI and NIHR funding on specific areas is provided in the table below: NIHRUKRIAcneNIHR allocated £2,148,574.06 for research concerning acne research in 2023-24.UKRI did not commit any specific funding for acne research in 2023-24.AlopeciaNIHR did not allocate any funds for research concerning alopecia research during 2023-24UKRI have committed £215,666 for alopecia research for a 3 year period commencing March 2024.PsoriasisNIHR allocated £858,946.12 for research concerning psoriasis research in 2023-24.UKRI have committed £300, 266 for psoriasis research for a 3 year period commencing February 2024 .PemphigusNIHR did not allocate any funds for research concerning pemphigus research during 2023-24UKRI did not commit any specific funding for pemphigus research in 2023-24.Atopic DermatitisNIHR allocated £2,045,996 for research concerning atopic dermatitis research in 2023-24.UKRI have committed £404,880 for atopic dermatitis research for a 3 year period commencing June 2023.Epidermolysis BullosaNIHR did not allocate any funds for research concerning epidermolysis bullosa research during 2023-24UKRI did not commit any specific funding for epidermolysis bullosa research in 2023-24.Hidradenitis SuppurativaNIHR has not allocated any funds for research concerning hidradenitis suppurativa research during 2023-24UKRI did not commit any specific funding for hidradenitis suppurativa research in 2023-24.SclerodermaNIHR allocated £155,575 for research concerning scleroderma research in 2023-24.UKRI did not commit any specific funding for scleroderma research in 2023-24.RosaceaNIHR did not allocate any funds concerning rosacea research during 2023-24UKRI did not commit any specific funding for rosacea research in 2023-24.VitiligoNIHR did not allocate any funds for research concerning vitiligo research during 2023-24UKRI did not commit any specific funding for vitiligo research in 2023-24.Basal Cell CarcinomaNIHR did not allocate any funds concerning basal cell carcinoma research during 2023-24UKRI did not commit any specific funding for basal cell carcinoma research in 2023-24.Squamous Cell CarcinomaNIHR allocated £1,467,858 for research concerning squamous cell carcinoma research in 2023-24UKRI did not commit any specific funding for squamous cell carcinoma research in 2023-24.MelanomaNIHR allocated £1,167,536 for research concerning melanoma research in 2023-24UKRI have committed £176,114 for melanoma research between March 24 and August 25.Actinic KeratosisNIHR did not allocate any funds concerning actinic keratosis research during 2023-24UKRI did not commit any specific funding for actinic keratosis research in 2023-24.

Innovation and Technology, what the total amount of Government investment into otitis media with effusion research was in 2023-24; and which public bodies provided that investment.

The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). We are committed to funding timely research that leads to improved outcomes for patients and the public and makes the health and social care system more efficient, effective and safe. Research evidence is vital for improving treatments and outcomes for people, including those who experience hearing problems and tinnitus Over the past five financial years (2019/20 – 2023/24), the NIHR has invested £3.3 million across 14 studies on these research topics directly through NIHR research programmes, with a further £1.1 million invested in career development and capacity for new hearing loss researchers. NIHR allocated £47,943 for research concerning otitis media and otitis media with effusion research in the financial year 2023-24. UKRI delivers a substantial portfolio of researcher-led projects. This includes biological, physiological, and mechanistic aspects that are applicable to many ear conditions. UKRI’s Medical Research Council (MRC) also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally.MRC funds Doctoral Training Partnerships, a range of postgraduate training, in 2017-2024, MRC awarded £106, 564 for injury in blast-induced hearing loss and tinnitus research. In 2022 MRC also committed £1,014,670 for age-related hearing loss research, this project is active until 2025.MRC Cognition and Brain Sciences Unit in Cambridge, supports two programmes of work that investigate the neural and cognitive mechanisms of hearing and speech (https://gtr.ukri.org/projects?ref=MC_UU_00030%2F4 and https://gtr.ukri.org/projects?ref=MC_UU_00030%2F6), as well as providing funding in 2023/24 for research into the different types of hearing loss https://gtr.ukri.org/projects?ref=MR%2FX019217%2F1.